Norovirus vaccine mRNA-1403 missed the Phase 3 interim efficacy bar in Moderna's Q2 2026 earnings disclosure Thursday, ...
CureVac and GSK have been racing behind Moderna to try to get the first mRNA flu vaccine to market. But, now, the European partners have come up against the exact same problem as their U.S. competitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results